Home›The Library›CJC-1295 vs Ipamorelin
CJC-1295 vs Ipamorelin
Both are unapproved growth-hormone secretagogues, commonly sold and stacked together — and both were formally rejected by the same FDA advisory committee for the same practical purpose, compounding eligibility. The two rejections rest on different evidence, though: one on a genuine, unresolved toxicity signal, the other on a clean negative efficacy trial.
On this page
In brief
Should you care? Yes, if either is being sold to you as "the safe one" or part of a routine stack. Neither has cleared FDA's own advisory review, and the two rejections happened for different reasons worth knowing separately.The short version
- CJC-1295: a real, human-confirmed GH/IGF-1 effect lasting days — rejected in December 2024 over nonclinical toxicity findings and an unresolved cardiac signal from a 2006 trial, not just a lack of data.
- Ipamorelin: marketed as the "gentle" secretagogue — its one real clinical-outcome trial found no benefit over placebo, and it was rejected in October 2024 for insufficient safety/efficacy evidence.
- Neither has a published trial for muscle gain, fat loss, sleep or longevity — the reasons people actually buy them.
Side by side
| CJC-1295 | Ipamorelin | |
|---|---|---|
| What it is | Modified GHRH(1-29) analog, DAC or no-DAC (Mod GRF 1-29) | Pentapeptide, selective ghrelin-receptor (GHS-R1a) agonist |
| Real human data | 2006 trial: single dose raised GH/IGF-1 for 6+ days (Teichman et al.) | 1999 Phase 1: dose-proportional GH release, ~2-hour half-life (Gobburu et al.) |
| Only clinical-outcome trial | None published | 2014 Phase 2, postoperative ileus: no benefit over placebo (Beck et al.) |
| FDA PCAC review date | 4 December 2024 | 29 October 2024 |
| PCAC outcome | Voted against 503A bulks list inclusion | Voted against 503A bulks list inclusion |
| Stated reasons | Nonclinical toxicity (pituitary-cell DNA damage, injection-site necrosis), an unresolved cardiac signal from a terminated 2006 HIV trial, immunogenicity risk | Insufficient safety/efficacy data for the proposed uses (GH deficiency, postoperative ileus) |
| WADA status | Prohibited (S2, GHRH-analogue class) | Prohibited (S2, growth hormone secretagogue class) |
Why they get stacked together
CJC-1295 and ipamorelin are two different mechanisms that both push the same downstream lever, growth hormone release, which is exactly why they're so often sold and injected together: a GHRH analog (CJC-1295) that extends the natural GH pulse alongside a ghrelin-receptor agonist (ipamorelin) that adds a second, complementary pulse. See each drug's own CJC-1295 and ipamorelin page for the full mechanism and evidence detail. That combined-mechanism logic is real pharmacology — it is not, on its own, evidence that the combination is safe or that it produces any of the outcomes (muscle gain, fat loss, better sleep, anti-aging) the stack is actually marketed for.
Two different rejections, not one
Both compounds went before FDA's Pharmacy Compounding Advisory Committee in late 2024 and came out the same way — rejected for the 503A bulks list, closing the path to lawful Category 1 compounding — but for meaningfully different reasons. Ipamorelin's 29 October 2024 rejection came down to an evidentiary gap: committee members cited a lack of information supporting safety and efficacy for the proposed uses (growth hormone deficiency and postoperative ileus), essentially "not enough has been shown," not a specific finding of harm. CJC-1295's 4 December 2024 rejection was different in kind: FDA's own briefing materials cited nonclinical toxicity findings (DNA damage in pituitary cells, injection-site inflammation and necrosis), immunogenicity risk, and an unresolved cardiac signal — a Phase 2 trial in HIV-associated wasting was halted after a participant death in 2006, which the attending physician attributed to likely undiagnosed coronary artery disease unrelated to the drug, but which was never formally resolved before the nomination for compounding eligibility was itself withdrawn in September 2024, ahead of the committee's vote. A rejection built on an actual toxicity signal is a different, more specific finding than a rejection built on an evidence gap, even though both end in the same practical place today.
Neither rejection is reversible by a vendor's marketing
Both compounds are sold online as "research chemicals," which does not create a lawful pathway around either rejection. See why RUO labelling doesn't change this.
What neither one has
Strip away the mechanism data and the regulatory history, and the same gap sits under both: no published clinical trial of either compound, alone or combined, has tested the outcomes they're actually sold for. CJC-1295's only human evidence is a pharmacodynamic finding — it raises GH and IGF-1, full stop, with no efficacy trial in the two decades since. Ipamorelin's only clinical-outcome trial exists, but it's a negative one, for a condition (postoperative bowel recovery) unrelated to why anyone actually buys it. A pharmacodynamic effect and a null efficacy result are both real findings — neither is evidence the stack does what it's marketed to do.
The honest bottom line
If you're being told one of these is "the safe one" and the other is "the risky one," the honest comparison doesn't support a clean split: both are unapproved, both were rejected by the same FDA process, and both lack any trial evidence for their marketed uses. The one real difference worth knowing is that CJC-1295's rejection rests on an actual toxicity and cardiac-safety signal that was never resolved, while ipamorelin's rests on the absence of supporting data rather than a specific finding of harm — a distinction worth knowing, not a reason to treat either one as cleared.
References
- Teichman et al., "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults," J Clin Endocrinol Metab 2006;91(3):799-805, PMID 16352683.
- Gobburu et al., "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers," Pharm Res 1999;16(9):1412-1416, PMID 10496658.
- Beck et al., "Randomized clinical trial of IV ipamorelin for postoperative ileus after colorectal resection," Int J Colorectal Dis 2014;29(12):1527-1534.
- FDA, Pharmacy Compounding Advisory Committee meeting and briefing materials, 29 October 2024 (ipamorelin) and 4 December 2024 (CJC-1295) — committee voted against both compounds' inclusion on the 503A bulks list; CJC-1295 briefing materials cite nonclinical toxicity findings, immunogenicity risk, and the unresolved cardiac signal from a terminated 2006 trial. See each drug's own CJC-1295 and ipamorelin page for the fully-cited detail summarised in the comparison table above.